<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>77</patient-age><report-id>US-SANOFI-AVENTIS-2013SA002985</report-id><gender>female</gender><reactions><reaction>bowel obstruction</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>MULTAQ</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10003658</indication></indications><patient-age>77</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78950</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125151855</messagedate>
</ichicsrmessageheader> 
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>US-SANOFI-AVENTIS-2013SA002985</safetyreportid>
<primarysourcecountry>US</primarysourcecountry>
<occurcountry>US</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>2013-01-25</transmissiondate>
<reporttype>1</reporttype>
<serious code="1">Yes</serious>
<seriousnessdeath>2</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>1</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<seriousnessother>2</seriousnessother>
<receivedateformat>102</receivedateformat>
<receivedate>2013-01-14</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>2013-01-14</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>US-SANOFI-AVENTIS-2013SA002985</companynumb>
<primarysource>
<reportertitle>MS.</reportertitle>
<reportergivename>NANCY</reportergivename>
<reporterfamilyname>ENGERMANN</reporterfamilyname>
<reporterstreet>3002 ESSEX ROAD</reporterstreet>
<reportercity>KALAMAZOO</reportercity>
<reporterstate>MI</reporterstate>
<reportercountry>US</reportercountry>
<qualification code="5">Consumer or non-health professional</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>NE</patientinitial>
<patientbirthdateformat>102</patientbirthdateformat>
<patientbirthdate>19350407</patientbirthdate>
<patientonsetage>77</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>6</patientagegroup>
<patientsex code="2">Female</patientsex>
<reaction>
<primarysourcereaction>bowel obstruction</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10006055</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>610</reactionstartdateformat>
<reactionstartdate>201211</reactionstartdate>
<reactionenddateformat>610</reactionenddateformat>
<reactionenddate>201211</reactionenddate>
<reactionfirsttime>1</reactionfirsttime>
<reactionfirsttimeunit>801</reactionfirsttimeunit>
<reactionoutcome code="1">recovered/resolved</reactionoutcome>
</reaction>
<drug>
<drugcharacterization code="1">suspsect</drugcharacterization>
<medicinalproduct>MULTAQ</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 22-425</drugauthorizationnumb>
<drugstructuredosagenumb>400</drugstructuredosagenumb>
<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
<drugseparatedosagenumb>2</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
<drugdosageform normalized="tablet">TABLET</drugdosageform>
<drugadministrationroute code="048">Oral</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10003658</drugindication>
<drugstartdateformat>610</drugstartdateformat>
<drugstartdate>2011-10-01</drugstartdate>
<drugstartperiod>1</drugstartperiod>
<drugstartperiodunit>801</drugstartperiodunit>
<actiondrug code="6">Not Applicable</actiondrug>
<activesubstance>
<activesubstancename>DRONEDARONE</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical><Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>information was received from a consumer on 14-Jan 2013:A <Semaphore x="1387834" class="Patient Age" value="77" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="77" score="1.00" ID="">77 </Semaphore>year old </Semaphore>female with an unknown medical history initiated <Semaphore x="509681" class="Medicine - dronedarone - Frequency" value="twice" score="0.49" ID=""><Semaphore x="509664" class="Medicine - dronedarone - Dose" value="400 mg" score="0.49" ID=""><Semaphore x="509699" class="Medicine" value="dronedarone" score="0.87" ID="249449">dronedarone </Semaphore>(<Semaphore x="890298" class="Medicine - Multaq - Dose" value="400 mg" score="0.49" ID=""><Semaphore x="890327" class="Medicine" value="Multaq" score="0.74" ID="279440">Multaq</Semaphore>) <Semaphore x="2188990211948545" class="Medicine - dronedarone - Dose" value="400 mg" score="0.49" ID="">400 mg </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2189063226392577" class="Medicine - dronedarone - Frequency" value="twice" score="0.49" ID="">twice </Semaphore></Semaphore>daily with meals for <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>in October 2011. In November 2012 she was in the hospital for 9 days with a <Semaphore x="1623372" class="Disease or Finding" value="Bowel Obstruction" score="1.00" ID="C9175">bowel obstruction</Semaphore>. For 5 days while in the hospital she was <Semaphore x="2754748" class="MedDRA LLT" value="Aphagia" score="1.00" ID="10049866">unable to eat </Semaphore>and she was given <Semaphore x="509699" class="Medicine" value="dronedarone" score="0.87" ID="249449">dronedarone </Semaphore>(<Semaphore x="890327" class="Medicine" value="Multaq" score="0.74" ID="279440">Multaq</Semaphore>) without food. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Therapy </Semaphore>with <Semaphore x="509699" class="Medicine" value="dronedarone" score="0.87" ID="249449">dronedarone </Semaphore>continued. Concomitant medications were not provided. No further relevant was provided.</narrativeincludeclinical>
<sendercomment>Sanofi Company Comment dated 14-Jan-2013: a 77-year old female patient with an unknown medical history had developed a bowel obstruction while being treated with Multaq (dronedarone) for about one year for atrial fibrillation. Limited information provided precludes an assessment of the case. Additional information such as details of the reported event and hospitalization with the results of the diagnostics performed, concomitant medications and medical history is needed and will be requested.</sendercomment>
</summary>
</patient>
</safetyreport> 
</ichicsr></original></faers>